Abstract:Introduction: G protein-coupled receptor (GPR) 40 is abundantly expressed in β cells. GPR40 and GPR120 are also expressed on the intestinal L cells and activating GPR40 and GPR120 can stimulate L cells to secret glucagon like peptide (GLP)-1. GW 9508 is a small-molecule agonist of GPR40 and GPR120. It dose dependently potentiates glucose-stimulated insulin secretion. In this study, we investigated whether GW9508 can directly stimulate β-cell replication in vitro and in vivo and improve islet graft function in diabetic mice. Methods: To determine β-cell proliferation in vitro, C57BL/6 mouse islets were cultured for 4 days, with and without GW9508. BrdU was added on day 3 for overnight. Insulin and BrdU immunofluorescence staining was performed on intact islets. Insulin+ and BrdU+ β cells were accounted using confocal microscope. To determine islet graft function, 100 C57BL/6 mouse islets were transplanted under the left kidney of each streptozotocin induced-diabetic C57BL/6 mouse. Recipient mice were orally treated with vehicle for GW9508 (containing dimethyl sulfoxide) or with GW9508 at 10 mg/kg/day, starting from the day of islet transplantation. All recipient mice were also intraperitoneally treated with BrdU at 100 mg/kg/day to label the replicated cells. Islet graft function was monitored by measuring blood glucose level. At 4 weeks, left nephrectomy was performed to remove the kidney bearing islet grafts to determine β-cell replication in islet grafts. Results: Insulin+ and BrdU+ β cells in each cultured islet were 13.6±1.2 cells with 0.1 μM GW9508; 18.3±1.5 cells with 1 μM GW9508; and 27.4±2.4 cells with 10 μM GW9508 (P< 0.01, vs. 10.5±0.6 cells in each untreated islet). At 2 week after islet transplantation, normoglycemia was achieved in 50% vehicle-treated mice achieved (n=10) and 100% GW9508-treated mice achieved normoglycemia (n=10). Although all recipient mice achieved normoglycemia at 4 weeks with or without treatment, normoglycemia was achieved in significantly fewer days in GW9508-treated mice. The vehicle-treated mice achieved normoglycemia in 14.4 ±2.9 days, while GW9508-treated mice only required 6.4±2.9 days (P< 0.01). The percentage of insulin+ and BrdU+ β cells in islet grafts were significantly higher in GW9508-treated mice than in vehicle-treated mice. The mean percentage of insulin+ and BrdU+ β cells in islet grafts was 23.6±6.4% in GW9508-treated mice and 6.7±3.4% in vehicle-treated mice (P< 0.01). At 30 minutes treatment, plasma GLP-1 was 9.3±2.6 pM/L in vehicle-treated mice and 14.7±4.7 pM/L in GW9508-treated mice (P< 0.05). Conclusion: Our data demonstrated that GW9508 can stimulate β-cell replication and improve islet graft function. Targeting GPR40 and/or GPR120 is a new therapeutic approach to stimulate β-cell replication and to improve islet graft function.

In Vivo Targeted Delivery of ANGPTL8 Gene for Beta Cell Regeneration in Rats

ANGPTL8 Reverses Established Adriamycin Cardiomyopathy by Stimulating Adult Cardiac Progenitor Cells.

Ultrasound-Targeted Microbubble Destruction Mediates Gene Transfection for Beta-Cell Regeneration and Glucose Regulation.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration Instreptozotocin-Induced Diabetic Baboons Usingultrasound-Targeted Microbubble Gene Therapywith Cyclind2/cdk4/glp1

Reversal of Streptozotocin-Induced Diabetes in Rats by Gene Therapy with Betacellulin and Pancreatic Duodenal Homeobox-1

Myocardial Regeneration in Adriamycin Cardiomyopathy by Nuclear Expression of GLP1 Using Ultrasound Targeted Microbubble Destruction.

Enhancement of the Anti-Apoptotic and Angiogenic Properties of Bone Marrow-Derived Endothelial Progenitor Cells by Bcl-2 Gene Transfer in Rats

Direct Transfer of A20 Gene into Pancreas Protected Mice from Streptozotocin-Induced Diabetes

Ang-(1-7) Improves Islet B Cell Function By Up-Regulating The Activity Of Ang-(1-7)-Mas Axis/Pdx-1

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

Angiopoietin-like protein 8: An attractive biomarker for the evaluation of subjects with insulin resistance and related disorders

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis.

Stimulating Beta Cell Replication and Improving Islet Graft Function by A Gpr40 and Gpr120 Dual Agonist

Vascular smooth muscle cells specific deletion of angiopoietin-like protein 8 prevents angiotensin II-promoted hypertension and cardiovascular hypertrophy

GLP-1 Receptor Agonists Stimulate ANGPTL8 Production Through the PI3K/Akt Pathway in a GLP-1 Receptor-Dependent Manner

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Β-Cell Regeneration in Situ in Type 1 Diabetic Mice

Enhancing human islet xenotransplant survival and function in diabetic immunocompetent mice through LRH-1/NR5A2 pharmacological activation